Abstract
I read the article by Pastori et al. [ [1] Pastori D. Pignatelli P. Saliola M. et al. Inadequate anticoagulation by Vitamin K antagonists is associated with major adverse cardiovascular events in patients with atrial fibrillation. Int. J. Cardiol. 2015; 201: 513-516 Abstract Full Text Full Text PDF PubMed Scopus (52) Google Scholar ] with great interest. In their artcile, the authors reported that inadequate anticoagulation by Vitamin K Antagonists was found to be associated with Major Adverse Cardiovascular Events (MACE) in patients with atrial fibrillation, and they concluded that time in therapeutic range (TTR) was an independent predictor of MACE in patients with atrial fibrillation. It is known that inadequate anticoagulation by Vitamin K Antagonists is a strong predictor of stroke. Pastori et al. identified the predictive value of inadequate anticoagulation for MACE. However, because of some confounding factors, I would like to emphasize some important points to clarify the findings of the present article. Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillationInternational Journal of CardiologyVol. 201PreviewTime in therapeutic range (TTR) reflects the quality of anticoagulation and is inversely correlated with ischemic stroke in atrial fibrillation (AF) patients. Few data on the relationship between TTR and myocardial infarction (MI) are available. We investigated the association between TTR and Major Adverse Cardiovascular Events (MACE) in a cohort of anticoagulated AF patients. Full-Text PDF Reply to: “Inadequate anticoagulation by vitamin K antagonists and major adverse cardiovascular events other than stroke”International Journal of CardiologyVol. 202PreviewWe have recently demonstrated that the quality of anticoagulation with vitamin K antagonists, expressed by the Time in Therapeutic Range (TTR) favourably influences the occurrence of major adverse cardiovascular events (MACE) in atrial fibrillation (AF) patients [1]. Dr. Eyuboglu raises the possibility that the use of anti-hypertensive drugs or blood pressure control may also be implicated in reducing MACE. Full-Text PDF
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
